Plasma lacosamide monitoring in children with epilepsy: Focus on reference therapeutic range and influencing factors

BACKGROUND: Lacosamide (LCM) is a newer anti-seizure medication (ASM) that was approved in China in 2018, but its real-world clinical data and plasma concentrations in Chinese children with epilepsy are very limited. Of note, the reference range for routine LCM therapeutic drug monitoring is still u...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yue, Guo, Hong-Li, Zhang, Yuan-Yuan, Dong, Na, Hu, Ya-Hui, chen, Jing, Lu, Xiao-Peng, Chen, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490115/
https://www.ncbi.nlm.nih.gov/pubmed/36160782
http://dx.doi.org/10.3389/fped.2022.949783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490115/
https://www.ncbi.nlm.nih.gov/pubmed/36160782
http://dx.doi.org/10.3389/fped.2022.949783

Ejemplares similares